Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Slides:

Advertisements

Similar presentations

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Advertisements

What's New in Basal Insulin for Diabetes

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM

Leveraging Registry Data: Uncovering Gaps and Discovering Opportunities to Improve How We Manage CVD Risk in Patients with T2DM Suzanne V. Arnold, MD,

The Latest Lipid Guidelines:

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Updates on CVOT Data and Clinical Comparisons That Matter

Global Projections for Diabetes:

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Managing Complex Hypertension: What Every Physician Should Know

Updates on Outcomes for Novel T2D Therapies

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Antithrombotics and PAD: A New Paradigm in Practice

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Emerging CVOT Data and Clinical Application

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

Metabolically Healthy Patients With Obesity

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Impacting CV Risk With Diabetes Medications

T2DM and CV Outcomes Trials: A Deep Dive!

Diabetes Increases Risk of CVD

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

The future of urate-lowering strategies for gout

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Tackling CV Risk in T2DM.

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Breaking Down the CVOTs

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Antihyperglycemic Therapy

Factor Xa Inhibitors in PAD

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Updates From ACC.

COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?

Add-On Therapy to Insulin in T1DM Management

Elevated Admission Plasma Glucose Following ACS

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Improving Overall Health

DECLARE-TIMI 58.

2015 EASD In Review: CV Risk management in t2dm

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

What's New in Oral Combination Therapy for Type 2 Diabetes?

Emerging Advances in Reducing Renal Complications of T2D

Lipids, the Heart, and the Kidney

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Top Tips in Evidence-Based Care for HFrEF

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines

Introduction/Overview

Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

Drug-Specific Factors to Consider When Selecting T2DM Therapy: Metformin

Decision Cycle for Patient-Centered Glycemic Management in T2DM

Agent Selection Criteria for Patients With T2DM Without ASCVD or CKD

Meta-Analysis of GLP-1 RA and SGLT2I Trials: CVD

Meta-Analysis of GLP-1 RA and SGLT2I Trials: HHF

Meta-Analysis of GLP-1 RAs and SGLT2s: CKD (Narrow Renal Endpoints)

Are SGLT2I Renal Benefits eGFR Dependent?

CREDENCE: Study Design and Results

EMPA-REG Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

EMPA-KIDNEY

Obesity as a Risk Factor for a Number of Disease States and Risk Factors

ACCORD -- Hypoglycemia

Clear-Cut Clinical Roles for SGLT2Is and GLP-1 RAs

Summary and Conclusions

Abbreviations

Abbreviations (cont)